Clinical trial

The Effects of Rotator Interval Hydro-dissection in Primary Adhesive Capsulitis. A Two-arm Double-blind Randomised Controlled Trial

Name
2023630-12612
Description
Adhesive capsulitis (AC) is a significant cause of chronic shoulder pain and disability. Non-surgical option consisting of intraarticular corticosteroid (IA CS) injection with structured physiotherapy (PT) is the current standard of care. More recent randomized controlled trials have found that rotator interval (RI) hydro-dissection approach leads to better improvement in pain as compared to IA approach. Despite being non-inferior to surgical management, long-term outcome studies of patients treated with IA CS injection and PT have shown that patients only achieve satisfactory outcomes in 72.3% of patients after a mean symptom duration of 41.8 months. Furthermore, CS injections are associated with significant systemic and local adverse effects such as Cushing syndrome, osteopenia/ osteoporosis, infection, and hyperglycemia. In recent years, dextrose injection has emerged as an effective alternative to CS-based injections to treat chronic painful musculoskeletal conditions such as chronic low back pain, peripheral nerve entrapment and lateral epicondylitis. The investigators aim to study the effects of RI hydro-dissection with dextrose 5% (D5%) on pain relief, shoulder ROM and shoulder function in patients with primary AC.
Trial arms
Trial start
2023-08-01
Estimated PCD
2024-07-01
Trial end
2025-07-01
Status
Not yet recruiting
Phase
Early phase I
Treatment
Rotator interval hydro-dissection with dextrose 5%
Single injection of 20ml dextrose 5% into the rotator interval around the long head biceps tendon under ultrasound guidance using a 11-14 Hz frequency linear probe
Arms:
Dextrose 5%
Rotator interval hydro-dissection with corticosteroid solution
Single injection of 20ml corticosteroid solution (1 ml triamcinolone 40 mg/ml + 19 ml saline 0.9%) into the rotator interval around the long head biceps tendon under ultrasound guidance using a 11-14 Hz frequency linear probe
Arms:
Corticosteroid
Size
60
Primary endpoint
Shoulder pain
1 week, 4 weeks and 12 weeks post injection
Eligibility criteria
Inclusion Criteria: * patients with primary adhesive capsulitis * aged 35 to 65 years of age * duration of symptoms in between 3 to 18 months * limitation in flexion, abduction, and external rotation greater than 30 degrees compared to normal * limitation in internal rotation with hand to back shoulder test below L4 Exclusion Criteria: * diagnosis of connective tissue disease or inflammatory arthritis * history of surgery to the affected shoulder * history of shoulder dislocation/ fracture * neurological weakness of the affected upper limb * ultrasound findings of rotator cuff or LHBT tendinopathy * plain radiographs showing significant glenohumeral joint osteoarthritis (Kallgren-Lawrence grade 3 or 4) * other sources of chronic pain * bilateral adhesive capsulitis * history of pain intervention to the shoulder joint in the past 3 months * allergic reaction to local anesthetic agent
Protocol
{'studyType': 'INTERVENTIONAL', 'phases': ['PHASE4'], 'designInfo': {'allocation': 'RANDOMIZED', 'interventionModel': 'PARALLEL', 'primaryPurpose': 'TREATMENT', 'maskingInfo': {'masking': 'TRIPLE', 'whoMasked': ['PARTICIPANT', 'INVESTIGATOR', 'OUTCOMES_ASSESSOR']}}, 'enrollmentInfo': {'count': 60, 'type': 'ESTIMATED'}}
Updated at
2023-08-07

1 organization

1 product

1 indication

Indication
Frozen Shoulder